Generics - Ophthalmics

Filter

Current filters:

Ophthalmics

Popular Filters

Pfizer to acquire generics firm InnoPharma for up to $360 million

Pfizer to acquire generics firm InnoPharma for up to $360 million

17-07-2014

Having failed (so far) in its mega billion dollar ($116 billion) attempt to buy Anglo-Swedish drug major…

GenericsInnoPharmaMergers & AcquisitionsOncologyOphthalmicsPfizer

Actavis confirms challenge to Allergan’s Restasis

22-01-2014

Generics drug major Actavis has confirmed that its Watson Laboratories unit has submitted an Abbreviated…

ActavisAllerganGenericsNorth AmericaOphthalmicsPatentsRegulationRestasisUSAWatson Pharmaceuticals

Akorn shells out $52.8 million for rights to three Merck drugs

Akorn shells out $52.8 million for rights to three Merck drugs

18-11-2013

USA-based niche generic drugmaker Akorn has acquired from pharma giant Merck & Co the US rights to three…

AkornAzaSiteCosoptGenericsMerck & CoMergers & AcquisitionsNorth AmericaOphthalmics

Sandoz appeals US court decision on AzaSite patent

Sandoz appeals US court decision on AzaSite patent

06-11-2013

US ophthalmic care specialist InSite Vision says that Sandoz Inc, the US generics unit of Swiss drug…

AzaSiteGenericsInSite VisionLegalNorth AmericaNovartisOphthalmicsPatentsSandoz

Back to top